March 29, 2020
The feasibility of convalescent plasma therapy in severe COVID-19 patients | Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up
The feasibility of convalescent plasma therapy in severe COVID-19 patients | Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up
Clinical Reports: Characteristics of Infected Children in Hubei, Case-fatality rate and characteristics of patients in Italy, functional exhaustion of antiviral lymphocytes
Antiviral Therapeutics: FDA approval for plasma treatment, convalescent sera option
Clinical: China retrospectives |
Therapies: Lopinavir-Ritonavir, Hydroxychoroquine and Azithromycin trials | Epidemiology: Non-pharmaceutical interventions, cryptic transmission | Environmental: Aerosol and surface stability
A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.
Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States.